Table 3.
Factors associated with severe adverse events in women initiating NVP-based antiretroviral therapy.
| All severe adverse events (N = 88)† | Severe hepatotoxicity(N = 10) | ZDV-related severe averse events (N = 71) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
| Age (years) | |||||||||
| ≥30 (n = 137) | 1.03 | 0.67-1.59 | 0.90 | 1.37 | 0.37-5.06 | 0.64 | 0.92 | 0.57-1.49 | 0.74 |
| <30 (n = 153) | 1.00 | - | - | 1.00 | - | - | 1.00 | - | - |
| Body mass index (Kg/m2) | |||||||||
| <18 (n = 40) | 1.08 | 0.53-2.20 | 0.05 | 1.12 | 0.52-2.42 | 0.78 | |||
| ≥18 (n = 160) | 1.00 | - | - | 1.00 | - | - | |||
| CD4+ count/mm 3 | |||||||||
| >250 (n = 88) | 0.68 | 0.41-1.12 | 0.14 | 1.75 | 0.48-6.39 | 0.40 | 0.64 | 0.36-1.14 | 0.13 |
| ≤250 (n = 202) | 1.00 | - | - | 1.00 | - | - | 1.00 | - | - |
| WHO staging | |||||||||
| Stage 3 or 4 (n = 130) | 1.00 | 0.63-1.58 | 0.99 | 1.31 | 0.36-4.74 | 0.68 | 1.07 | 0.65-1.79 | 0.77 |
| Stage 1 or 2 (n = 160) | 1.00 | - | - | 1.00 | - | - | 1.00 | - | - |
| ALT (IU/L) | |||||||||
| ≥31(n = 50) | 1.58 | 0.89-2.78 | 0.12 | 7.09 | 1.59-31.62 | 0.01 | 1.10 | 0.57-2.15 | 0.78 |
| <31(n = 240) | 1.00 | - | - | 1.00 | - | - | 1.00 | - | - |
| Neutrophil level (/mm3) | |||||||||
| <1500 (n = 28) | 1.51 | 0.76-2.98 | 0.24 | 2.20 | 1.09-4.43 | 0.03 | |||
| ≥1500 (n = 262) | 1.00 | - | - | 1.00 | - | - | |||
| Hemoglobin level (g/dL) | |||||||||
| ≤9.8 (n = 150) | 1.15 | 0.73-1.82 | 0.56 | 0.66 | 0.16-2.79 | 0.57 | 1.35 | 0.81-2.23 | 0.25 |
| >9.8 (n = 140) | 1.00 | - | - | 1.00 | - | - | 1.00 | - | - |
| Status of pregnancy | |||||||||
| Pregnant (n = 125) | 0.98 | 0.60-1.64 | 0.98 | 1.22 | 0.22-6.62 | 0.82 | 1.11 | 0.65-1.91 | 0.70 |
| Non pregnant (n = 165) | 1.00 | - | - | 1.00 | - | - | 1.00 | - | - |
Multivariable Cox regression analyses. MTCT-Plus program, Abidjan, Côte d'Ivoire (2003-2006).
HAART: Highly active antiretroviral therapy; WHO: World Health Organization; IQR: interquartile range; NVP: nevirapine; ALT: alanine aminotransferase; OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval, † If a woman had multiple severe adverse event